What Are Tirzepatide Injection Vials?
Tirzepatide is the active ingredient in Eli Lilly's branded medication Zepbound, the only FDA-approved dual GIP and GLP-1 receptor agonist for chronic weight management. The tirzepatide vials available through Vitercure contain the same active ingredient but come in single-dose injection vials rather than prefilled pens. They are dispensed by licensed USA and UK pharmacy partners and require drawing each weekly dose into a syringe.
How Tirzepatide's Dual Mechanism Works
GIP ReceptorGIP acts on fat cells and appetite centers in the brain. Researchers believe this is why tirzepatide outperforms GLP-1-only medications in head-to-head trials.
GLP-1 ReceptorGLP-1 signals fullness to the brain, slows stomach emptying, and regulates blood sugar after meals. These are the same benefits you get from Wegovy and Ozempic, amplified by the dual mechanism.
Who Are Tirzepatide Vials For?
Tirzepatide vials may be considered for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition, who are comfortable with syringe-drawn injections. Some patients prefer vials due to availability, pricing, or personal preference. A Vitercure clinician reviews your full history before any prescription is issued.
Tirzepatide Vials vs Zepbound Pens: Key Differences
Both deliver tirzepatide subcutaneously once weekly. The difference is the delivery format, preparation steps, and source.
| Feature | Tirzepatide Vials (this page) | Zepbound Pens (Eli Lilly) |
|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Licensed pharmacy partners (USA/UK) | Eli Lilly and Company |
| Delivery format | Single-dose vial, draw into syringe | Prefilled multi-dose pen, ready to inject |
| Preparation | Yes, draw dose and assemble syringe | Minimal, attach needle and inject |
| Doses per unit | 1 vial = 1 weekly dose (pack of 4) | 1 pen = 4 weekly doses |
| Available strengths | 2.5, 5, 7.5, 10, 12.5, 15mg | 2.5, 5, 7.5, 10, 12.5, 15mg |
| Best suited for | Patients comfortable with syringe draw, pen supply constraints, flexible pricing | Patients preferring auto-inject convenience, assured branded supply |
Are tirzepatide vials compounded tirzepatide?
No. The vials on this page are not compounded tirzepatide from 503A or 503B compounding pharmacies. They are tirzepatide in single-dose vial form from licensed, regulated pharmacy partners. Compounded tirzepatide is a separate and legally distinct category. Discuss the differences with your Vitercure clinician.
How to Use Tirzepatide Vials
Injection Steps
- Gather supplies: clean vial, new syringe and needle, alcohol swabs, sharps container. Wash hands thoroughly.
- Wipe the vial top with an alcohol swab. Insert the needle, invert the vial, and draw up the exact weekly dose as instructed by your prescriber.
- Clean the injection site (abdomen, thigh, or upper arm) with an alcohol swab. Rotate sites weekly.
- Pinch the skin, insert the needle at a 45 to 90 degree angle, and inject slowly and steadily.
- Place the needle and syringe immediately into a sharps container. Never reuse. Never inject a second time from the same single-dose vial.
Dose Titration Schedule
| Period | Weekly Vial Strength | Purpose |
|---|
| Weeks 1 to 4 | 2.5mg | Starting dose to help your body adjust. |
| Weeks 5 to 8 | 5mg | First step up if tolerated. SURMOUNT-1: 16% avg at 72 weeks. |
| Weeks 9 to 16 | 7.5mg | Mid-range therapeutic dose. |
| Weeks 17 to 24 | 10mg | SURMOUNT-1: 20.9% avg at 72 weeks. |
| Weeks 25 to 32 | 12.5mg | Near-maximum dose for eligible patients. |
| Week 33 onward | 15mg | Maximum dose. 22.5% avg at 72 weeks in SURMOUNT-1. |
Important Safety Information for Tirzepatide Vials
This is not a complete list of warnings or side effects. Always review the full Prescribing Information and speak with a licensed clinician.
Do Not Use If:
- You or a family member has a history of medullary thyroid carcinoma (MTC).
- You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- You have had a serious allergic reaction to tirzepatide.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, decreased appetite, and stomach discomfort. Usually worst during dose escalation and tend to improve. Slow titration as supervised by your clinician is the main management strategy.
Vial-Specific Safety
Single-dose vials must not be reused. Each vial contains one weekly dose. Discard in a sharps container after use. Do not combine remaining content from multiple vials. Use only the prescribed volume as drawn up according to your pharmacy's instructions.
Frequently Asked Questions About Tirzepatide Vials
They contain the same active ingredient, tirzepatide, but they are not the branded Zepbound prefilled pens manufactured by Eli Lilly. These are single-dose tirzepatide vials from licensed USA and UK pharmacy partners. The dose strengths and titration schedule are the same as those used in the SURMOUNT trials.
No. The vials on this page are not compounded tirzepatide from 503A or 503B compounding pharmacies. They are tirzepatide in single-dose vial form from licensed, regulated pharmacy partners. Compounded tirzepatide is a legally distinct category. Your Vitercure clinician can explain the differences.
Because they contain the same active ingredient as Zepbound, the SURMOUNT-1 data is the most relevant benchmark: average 22.5% body weight lost at 15mg over 72 weeks with diet and exercise. At 10mg the average was 20.9%, and at 5mg it was 16.0%. Individual results vary significantly.
Some patients choose vials because of pen supply shortages in their area, pricing differences, or personal preference for vial-based injection. Vials require drawing each dose into a syringe, which takes a couple extra minutes but delivers the same therapeutic effect.
Yes. Through Vitercure, eligible adults can complete a brief online questionnaire, consult with a licensed clinician, and if appropriate, receive a tirzepatide prescription fulfilled in single-dose vials by licensed USA or UK pharmacy partners with cold-chain shipping.
The SURMOUNT-4 trial showed that patients who stopped tirzepatide after 36 weeks regained most of the weight they had lost within about a year. Appetite and food cravings typically return. You should never stop without talking to your clinician first.
